相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
S. Hager et al.
ANNALS OF ONCOLOGY (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Heather H. Cheng et al.
EUROPEAN UROLOGY (2016)
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
Jonathan Welti et al.
EUROPEAN UROLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Zhenfei Li et al.
NATURE (2016)
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
J. L. Donovan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Raphael Ceccaldi et al.
CANCER RESEARCH (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Elena Castro et al.
EUROPEAN UROLOGY (2015)
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Roberta Ferraldeschi et al.
EUROPEAN UROLOGY (2015)
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Eleni Efstathiou et al.
EUROPEAN UROLOGY (2015)
Sequencing of agents in castration-resistant prostate cancer
David Lorente et al.
LANCET ONCOLOGY (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
Angela K. Green et al.
ONCOLOGIST (2015)
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
Emma L. Simpson et al.
PHARMACOECONOMICS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase Ill OVATURE multicenter randomized study
C. Fotopoulou et al.
ANNALS OF ONCOLOGY (2014)
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
D. Lorente et al.
BRITISH JOURNAL OF CANCER (2014)
Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis
Shae Ryan et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader et al.
EUROPEAN UROLOGY (2014)
Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study
Robert J. van Soest et al.
EUROPEAN UROLOGY (2014)
Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
John M. Fitzpatrick et al.
EUROPEAN UROLOGY (2014)
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer
Sergio Bracarda et al.
FUTURE ONCOLOGY (2014)
Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells
Olga Azarenko et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Colin C. Pritchard et al.
NATURE COMMUNICATIONS (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot et al.
ANNALS OF ONCOLOGY (2013)
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Jean Hoffman-Censits et al.
CLINICAL CANCER RESEARCH (2013)
Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases
Michel D. Wissing et al.
CLINICAL CANCER RESEARCH (2013)
Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands
Michel D. Wissing et al.
CLINICAL GENITOURINARY CANCER (2013)
Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
Axel Heidenreich et al.
EUROPEAN UROLOGY (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer
Giuseppe Di Lorenzo et al.
BJU INTERNATIONAL (2012)
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
Maisa Yoshimoto et al.
GENES CHROMOSOMES & CANCER (2012)
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
Marie L. Huber et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Importance of Supportive Care in Optimizing Treatment Outcomes of Patients with Advanced Prostate Cancer
Florian Scotte
ONCOLOGIST (2012)
Prostate cancer pain management: EAU guidelines on pain management
Pia Bader et al.
WORLD JOURNAL OF UROLOGY (2012)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S. Darshan et al.
CANCER RESEARCH (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
Bostjan Seruga et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2
Rodrigo Dienstmann et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2011)
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
A. H. M. Reid et al.
BRITISH JOURNAL OF CANCER (2010)
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
David J. Gallagher et al.
CLINICAL CANCER RESEARCH (2010)
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells
Meng-Lei Zhu et al.
FASEB JOURNAL (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Cabazitaxel
Matthew D. Galsky et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer
A. Sella et al.
ONCOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
X. Pivot et al.
ANNALS OF ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice
Mei-Ling Chen et al.
GENES & DEVELOPMENT (2006)
Secondary hormonal therapy for advanced prostate cancer
JS Lam et al.
JOURNAL OF UROLOGY (2006)
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
G Attard et al.
BJU INTERNATIONAL (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence
G Ayala et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
